Report blames NICE for hastening decline of UK biotech.
Moran
Nuala
N
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001709:Biotechnology / Q000639:trends; D001943:Breast Neoplasms / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D017277:Drug Approval / Q000706:statistics & numerical data*; D005260:Female; D006077:Government Agencies; D006801:Humans; D009313:National Health Programs; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D013673:Technology Assessment, Biomedical / Q000379:methods / Q000706:statistics & numerical data; D000068878:Trastuzumab; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human